Several human immunodeficiency virus type 1 (HIV-1) antigenic formulations have been tested in animal models and clinical trials, but the immunogenicity and protection achieved to date are still far from the desired goals for an HIV-1 vaccine. While the correlates of immune protection are still only vaguely defined, it is now generally recognized that an effective HIV-1 vaccine must elicit strong T-cell responses as well as neutralizing antibody [1] [2] [3] [4] . It has been postulated that the immunogenicity of a protein antigen can be enhanced by targeting the antigen to the major histocompatibility complex type II (MHC II) processing compartment of professional antigen-presenting cells (APCs). One of the approaches is the use of the lysosomal associated membrane protein-1 (LAMP) as a LAMP/antigen chimera to target endogenous antigens to the MHC II processing compartment [5] [6] [7] [8] [9] [10] . Many laboratories have reported that LAMP targeting can greatly enhance the immune responses against a number of antigens, including HPV-16-E7 and E6 proteins; human telomerase reverse transcriptase (hTert); West Nile virus preM-E; the thyroid hormone receptor (TSHR); HIV-1 Gag, Env gp120, Env gp160, and Nef; human melanosomal antigen (MAGE-3); dengue 2 preM-E; listeriolysin O; and SARS coronavirus N protein [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] .
Several approaches have been used to design DNA vaccines encoding LAMP/antigen chimeras. One frequently used construct contains the transmembrane and cytoplasmic (TMCy) domains of LAMP added to the C-terminus of the protein antigen. More recently, we have found that some antigens, including HIV-1 Gag, must be incorporated into the entire LAMP molecule in order to effect enhanced antigen expression and trafficking to the lysosomal Academic Editor: Douglas Nixon, University of California, San Francisco, United States of America compartment. Several LAMP/antigen chimeras, including proteins of West Nile, dengue, SARS CoV, HPV and HIV-1, have been shown to co-localize in vitro with MHC II, LAMP-1, LAMP-2, and H-2M in multiple cell types by confocal imunofluorescense microscopy, and/or by immunogold electron microscopy [11] [12] [13] [14] [15] [16] 24] .
The immunological benefits of LAMP-targeted antigens have been demonstrated in several mouse strains and, most importantly, also in humans [25] [26] . LAMP/antigen chimeras have been shown to induce increased CD4 + responses to the antigens in several assay systems, producing increased secretion of IL-2, IL-4, IL-5 and IFN-c cytokines; increased proliferative responses; a greater number of spot-forming cells (SFCs) in ELISPOT assays; intracellular cytokine staining (ICS); higher precursor frequencies; increased functional avidity and a broader response repertoire [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] .
The increased CD4 + -mediated responses produced by the LAMP/chimeras are thought to play an important role in modulating B-cell, CD8 + responses and the development of immune memory [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . When compared to the non-targeted molecules, LAMP/antigens elicited greatly increased antibody titers, viral neutralization, antibody affinity and numbers of B-cell epitopes recognized. CD8 + responses were also enhanced in several LAMP/antigen chimeric systems, as assessed by tetramer staining, IFN-c ELISPOT, chromium release, and the functional avidities and T-cell response repertoires of CD8 + cells. The longevity of the immunological memory of B cells and CD8 + cells is also increased in animals immunized with LAMP/chimeras.
Previous studies of HIV-1 DNA antigen formulations have described an HIV-1 p55gag DNA vaccine that elicited strong, broad and poly-functional cellular and humoral immune responses in immunized mice when the Gag sequence was incorporated into the complete LAMP cDNA sequence and the coding sequences were bracketed by the inverted terminal repeat (ITR) sequences of adeno-associated virus (AAV) [14] [15] [16] . These observations in mice led us to investigate the immunogenicity of a naked DNA encoding the HIV-1 LAMP/gag antigen formulation in Rhesus macaques, a relevant animal model for testing HIV vaccines for potential use in humans. We found that immunization of these primates with a human LAMP/gag (hLAMP/gag) DNA vaccine promoted a humoral and cellular immune response, which was associated with a sustained activation of B-lymphocytes as well as CD4 + and CD8 + T cells. Furthermore, Gag-specific T cells were detected after only two immunizations and were further expanded by booster injections of hLAMP/gag chimera. These results substantiate the usefulness of the LAMP vaccination strategy as a means of effectively eliciting T-and B-cell responses to naked DNA immunization of Rhesus macaques.
The mouse LAMP/gag (mLAMP/gag) plasmid was constructed as described previously [16] : Nucleotides 1-1503 of the HIV-1 HXB2 p55gag gene (GenBank TM accession number K03455; HIV sequence database, Los Alamos National Laboratory Theoretical Biology and Biophysics, Los Alamos, NM, USA) was inserted into the pITR vector [27] , which contains the AAV-ITR flanking the expression elements (cytomegalovirus promoter and bovine growth hormone polyadenylation signal). The p55gag sequence was inserted between the luminal domain and the TMCy domain of mouse LAMP (mLAMP) (GenBank TM accession number J03881), as described previously [16] . In the present study, the complete mLAMP cDNA described above was replaced by the human LAMP-1 (hLAMP) cDNA (GenBank TM accession number NM005561).
The control plasmids, consisting of mLAMP and hLAMP, were constructed using the respective complete LAMP sequences without Gag. The hLAMP/gag plasmid used for vaccination of Rhesus macaques was produced by Quality Biological Inc. (Gaithersburg, MD, USA), with a DNA purity of 96% and endotoxin level of 0.33 EU/mg.
Human 293 cells were plated in 6-well plates (2610 6 cells/well) and transfected with plasmid DNA (4 mg) using the FuGENE TM 6 (Roche Applied Science, Indianapolis, IN, USA) transfection reagents according to the manufacturer's instructions. The western blot analysis was done as previously described [15] .
Evaluation of hLAMP/gag targeting by confocal microscopy MHC II (I-Ek)-expressing cells (DCEK.ICAM.Hi7, a gift of Dr. Susan Swain, The Trudeau Institute, Saranac Lake, NY, USA) [28] were plated onto poly-lysine-coated coverslips in 6-well plates (2610 6 cells/well) and incubated overnight. The cells were transfected with the DNA plasmids using Lipofectamine TM 2000 transfection reagent (Invitrogen Life Technologies, Carlsbad, CA, USA), and 24-48 h later they were stained to evaluate cellular localization. Coverslips were fixed in 2% paraformaldehyde in phosphate-buffered saline (PBS) for 5 min and washed with PBS, then blocked and permeabilized with PBS containing 4% normal goat serum and 0.1% saponin. For detection of Gag expression, the cells were incubated for 1 h with mouse anti-Gag monoclonal antibody (provided by Dr. James Hildreth, Johns Hopkins School of Medicine, Baltimore, MD, USA) at a 1:50 dilution. After three washes with 0.1% saponin in PBS, the cells were incubated for 1 h with Texas Red-labeled goat anti-mouse IgG (BD Pharmingen, San Diego, CA, USA) at a 1:500 dilution. Co-localization of the hLAMP/gag chimera with MHC II of the transfected DCEK cells was performed by double immunostaining, first for the hLAMP/ gag chimera proteins as described above and followed by anti-MHC II, by incubating the cells for 1 h with FITC-labeled goat antimouse I-Ek (14-4-4S) (BD Pharmingen) at a 1:75 dilution. The cells were then washed three times with PBS, and the coverslips were mounted onto glass slides using ProLong Antifade reagent (Molecular Probes, Eugene, OR, USA). Confocal microscopy was performed using a Wallac confocal laser scanning microscope. Colocalization of the proteins with MHC II was thus determined by merging fluorophore images individually captured and digitally colored by use of Adobe Photoshop 7.0 (Adobe System Corp., San Jose, CA, USA).
Immunization of mice Female BALB/c mice, 6-8 weeks of age, were obtained from Charles River (Kingston, NY, USA). Mice in groups of eight were each immunized twice (21 days apart), intramuscularly (i.m.), with 50 mg of the indicated plasmid and sacrificed 7 days later. For CD8 + experiments, the mice were challenged 21 days after the first immunization with a VDK-1 vaccinia virus plasmid containing the native Gag sequence (10 7 plaque-forming units; NIH AIDS Research and Reference Reagent Program, Rockville, MD, USA).
Antibody responses Mouse serum was obtained from the tail vein 7 days after the second immunization. Serum IgG levels were measured by enzyme-linked immunosorbent assay (ELISA) as described previously [16] .
Preparation of splenocytes for assaying the T-cellmediated immune responses of immunized mice Singlecell suspensions depleted of red blood cells were prepared from freshly isolated mouse splenocytes in culture medium (RPMI medium 1640 supplemented with 5% v/v FBS, 100 U/ml penicillin/streptomycin, 2 mM glutamine, 50 mM 2mercaptoethanol, and 0.01 M HEPES buffer). Splenocytes were counted and resuspended at 10610 6 cells/ml in culture medium for T cell-mediated assays. T-cell responses of immunized mice were measured as described previously [15] .
Rhesus macaques Five healthy 4-to 8-kg male Rhesus macaques were maintained in the non-human primate facility of Southern Research Institute, Frederick, MD, USA. Animal care and treatment were in accordance with standards approved by the Institutional Animal Care and Use Committee, according to the principles set forth in the Guide for the Care and Use of Laboratory Animals, National Research Council, National Academy Press, 1996.
Immunization of macaques Each animal was immunized intramuscularly (i.m.) five times at weeks 0, 4, 14, 22 and 38 with 5 mg of hLAMP/gag DNA plasmid using a biojector, and 18 blood samples were drawn over the 42 week experiment period. Mucosal samples including mouth swabs, nasal and rectal washes were collected after four DNA immunizations. Blood and mucosal samples of non-immunized macaques were supplied periodically as controls.
Isolation of peripheral blood mononuclear cells (PBMCs) PBMCs were isolated by centrifugation (4006g, 40 min) on a Ficoll-Hypaque gradient (Amersham Biosciences Piscataway, NJ, USA). Mononuclear cells were collected from the interface and washed three times in cold phosphate-buffered saline with Ca 2 + and Mg 2 + (GIBCO, Grand Island, NY, USA). Residual red blood cells were removed with ACK lysing buffer (Quality Biological Inc., Gaithersburg, MD, USA). PBMCs to be used for cytokine analysis or ELISPOT assay were resuspended in supplemented culture medium (RPMI 1640 medium containing 1% FBS, 100 U/ml penicillin/streptomycin, and 2 mM Lglutamine).
CD8 + lymphocyte separation Positive selection of cells expressing CD8 + antigen was performed with monoclonal antihuman CD8 + conjugated to R-phycoerythrin (PE) and microbeads conjugated to monoclonal anti-PE antibodies (CD8 MicroBead kit, Miltenyi Biotec, Bergisch Gladbach, Germany) as described by the manufacturer. The CD8 + cells were .98% pure as assessed by flow cytometry. Fractionated cells were suspended in RPMI-10 medium and used on the same day for ELISPOT assay.
HIV Gag-specific IFN-c ELISPOT assay The frequency of IFN-c-producing CD4 + or CD8 + T cells from immunized Rhesus macaques was measured by ELISPOT assays, using the IFN-c ELISPOT set from BD-Biosciences Pharmingen according to the manufacturer's protocol. Initially, ELISPOT plates were coated with anti-human IFN-c Ig at 5 mg/ml and incubated at 4uC overnight. After blocking with RPMI-1640 containing 10% FBS for 2 h at room temperature (RT), total PBMCs (3610 5 cells/well) were cultured with hybridoma serum-free medium (GIBCO) supplemented with 1% FBS, 100 U/ml penicillin/streptomycin and 2 mM L-glutamine, in the presence of 10 mg/ml of HIVSF2 p55 gag recombinant protein (rGag); or HIV gag 15-amino acids (aa) peptides overlapping by 11-aa; or 20-aa overlapping by 10-aa. A negative control included in each assay consisted of medium lacking HIV antigen. Phytohemagglutinin (PHA) (Sigma, St. Louis, MO, USA) at 5 ng/ml with 500 ng/ml ionomycin (Sigma) was included as a positive control for each Rhesus macaque. After 16 h of culture, the plates were washed and incubated with biotinylated anti-human IFN-c for 2 h at RT, followed by HRPconjugated avidin for 1 h at RT. The reaction was developed with 3-amino-9-ethylcarbozole substrate (Calbiochem-Novabiochem Corporation, San Diego, CA, USA). Analysis of the IFN-c levels was performed using an immunospot image analyzer (Cellular Technology Limited, Cleveland, OH, USA). Background spots obtained with medium alone were subtracted from each experimental value. All results were expressed as mean number of SFC per 10 6 PBMCs. For each antigen, a responder Rhesus macaque was defined as one exhibiting a significant number IFN-c SFC cells over the background value or value for non-immunized macaques, at any time point over the immunization course.
Analysis of IL-6 secretion by capture ELISA Total PBMCs (5610 5 cells) from immunized macaques were cultured in a 96well plate (Nunc, Roskilde, Denmark) containing recombinant human IL-2 (500 U/well). Except for the negative and positive control wells containing culture medium alone and 5 ng/ml PHA (Sigma) containing 500 ng/ml ionomycin, respectively, PBMCs were stimulated with 10 mg/ml HIVSF2 p55 rGag. After a 48-h incubation at 37uC in 5% CO 2 , the supernatants were collected for detection of secreted cytokines and stored at 220uC until further use. IL-6 concentrations were determined using a monkey IL-6 OptEIA TM set (BD Pharmingen).
HIV Gag-specific humoral and mucosal immune responses Serum samples were tested throughout the experimental period for the presence of binding antibody to HIV Gag. Nunc plates were coated with 5 mg/ml HIVIIIB lysate in sodium carbonate-bicarbonate buffer, pH 9.4 (Pierce, Rockford, IL, USA). After overnight incubation at 4uC, the solution was removed, and the plates were washed six times with PBS containing 0.05% Tween-20 (PBS-T) wash buffer. The plates were then incubated for 2 h at 37uC with blocking buffer (PBS-T with 5% FBS) and then washed three times with PBS-T. IgG responses were measured with four serial 1:3 dilutions, starting at 1:100, in blocking buffer. IgA responses in serum, nasal, mouth and rectal washes were measured with 100 ml of 10-fold diluted sample added to the blocked plate in duplicate. The plates were incubated overnight at 4uC. After six washes, 100 ml of horseradish peroxidase-conjugated rabbit anti-monkey IgG (Sigma) diluted 1:5000 in blocking buffer was added to each well. For the detection of IgA antibodies, 100 ml of goat antimonkey IgA (Nordic Immunology, Tilburg, Netherlands) diluted 1:5000 in blocking buffer was added to each well. The plates were incubated for 2 h at 37uC and washed eight times with washing buffer. Turbo TMB substrate solution (BD Pharmingen) was then added to each well and incubated for 15 min at RT. The reaction was stopped by adding 100 ml of 1 M sulfuric acid, and absorbance at 450 nm was measured in a BIO-RAD model 3550 microplate reader.
B-cell epitope mapping HIV-1 Gag 20-aa peptides, spanning residues 1 to 490 with a 10-aa overlap (NIH AIDS Research and Reference Reagent Program), were diluted in 0.1 M sodium carbonate-bicarbonate buffer, pH 9.4, to give a concentration of 5 mg/ml, and 50 ml of the individual peptide was added to each well of a 96-well plate, in duplicate. After overnight incubation at 4uC, the solution was removed, and the plates were washed six times with PBS-T. They were then incubated with blocking buffer for 2 h at 37uC and washed three times. Serum samples (100 ml of a 1:300 dilution in blocking buffer) were added to each well, and the plates were incubated overnight at 4uC. After the plates were washed six times, 100 ml of HRP-conjugated rabbit anti-monkey IgG (Sigma), diluted 1:5000 in blocking buffer, was added to each well. The plates were incubated for 2 h at 37uC and then washed. Turbo TMB substrate solution (BD Pharmingen) was added to each well and incubated for 15 min at RT. The reaction was stopped by adding 100 ml of 1 M sulfuric acid, and absorbance at 450 nm was measured in a BIO-RAD model 3550 microplate reader.
Statistical Analyses All the graphs were made using GraphPad Prism Version 4.0a for Macintosh (GraphPad software, San Diego, CA, USA).
LAMP/Gag expression and cellular trafficking to the cellular MHC II compartment has been repeatedly demonstrated in studies with murine LAMP chimeras [11] [12] [13] [14] [15] [16] . The present study confirmed the similar expression and trafficking of the human LAMP/Gag protein chimera. Western blotting with anti-Gag antibody showed the presence of ,200 kDa LAMP/Gag protein at comparable levels in 293 cells transfected with either mouse or human LAMP/gag ( Figure 1A ). There appeared to be increased degradation of Gag in the hLAMP/gag transfected cells; however, the significance of this is not known as the results of other similar studies of mLAMP/gag transfected cells have shown variable levels of Gag degradation products [14] [15] [16] . Co-localization of the hLAMP/gag chimera transgene product with the cellular MHC II was confirmed with transfected DCEK cells stained with anti-Gag and anti-MHC II monoclonal antibodies ( Figure 1B) . 
Verification of the in vivo immune responses to the hLAMP/gag chimera and a comparison of the responses to mLAMP/gag were examined with mice immunized on days 1 and 21 with 50 mg DNA of the pITR plasmid vectors encoding the mLAMP/gag and hLAMP/gag chimeras. Total anti-Gag IgG responses were assayed with blood collected on day 28 (Figure 2A ). The response of mice immunized with the hLAMP/gag construct was considerably greater than the response to the mLAMP/gag.
Splenocytes of mice sacrificed after the two immunizations were assayed for T-cell IFN-c responses. The MHC II-targeted mouse and human LAMP/gag plasmids elicited comparable IFN-c + responses (8000 pg/ml and 6000 pg/ml, respectively) ( Figure 2B) .
Assays of CD8 + T-cell responses were carried out with mice immunized once with 50 mg of the plasmid DNA, followed 21 days later by in vivo expansion of Gag-specific T cells through inoculation with recombinant vaccinia-Gag-Pol (rVVGag-Pol). Five days later, the mice were injected with an immunodominant H-2Kdrestricted Gag peptide epitope and sacrificed after 2 h for the ex vivo assay. Mice immunized with both the mouse and human LAMP/gag chimeras uniformly developed significantly strong CD8 + responses as measured by epitope-specific CD8 + tetramer binding, intracellular IFN-c staining, and CTL lysis of peptidepulsed target cells ( Figure 2C ). The larger fraction of CD8 + T cells expressing IFN-c (.20%) following inoculation with recombinant vaccinia virus encoding Gag, in comparison with the proportion of tetramer positive cells, is attributed to the massive in vivo expansion of Gag-activated CD8 + T cells reactive against several other Gag MHC I epitopes, besides the immunodominant H-2Kd-AMQMLKETI peptide-tetramer epitope complex. The magnitude of the vaccine-induced T-cell responses varied from macaque to macaque; however, in every case, IFN-c secretion was detected after the second immunization at week 8, reached the highest level of 600 to 1200 SFC/10 6 cells at week 18 following the third immunization, and declined gradually until further immunizations were given at weeks 22 and 38 ( Figure 4) . These studies included an analysis of the relative efficiency of the 15-or 20-aa peptides in stimulating T-cell responses in vitro, and we observed that PBMCs of all the five immunized macaques stimulated with the 15-and 20-aa Gag peptide pools separately, showed no significant difference in the IFN-c response ( Figure 5 ). CD4 + -specific responses were also studied by ELISPOT analyses with CD8 + -depleted PBMC stimulated with rGag. All five macaques showed a response in the range of 200-1000 IFN-c + SFC/10 6 CD8 + -depleted cells, indicating a potent CD4 + -mediated response ( Figure 6 ).
The repertoire of peptide-specific responses elicited by lysosomal targeting in BALB/c mice has been shown to include the same immunodominant epitopes as those elicited by the native antigen; however, the chimeric antigen commonly elicits enhanced and additional T-cell responses that were not detected with the native antigen [24] . In an analysis of the potential effect of LAMP targeting on the breadth of the T-cell repertoire in macaques, PBMCs from the immunized macaques were tested at week 20, after 3 DNA immunizations, for T-cell responses to 12 different pools consisting of ten peptides each, of the 15-aa Gag peptide set (Figure 7) . T-cell responses to specific peptides were detected with each of the four immunized macaques that were included in this study. Three of the immunized macaques showed responses to five to eight of the peptide pools. One of the animals, macaque #3162, showed activation of IFN-c + cells in response to all of the peptide pools. Collectively, these data suggest that hLAMP/gag can prime a broad T-cell response in primates.
One remarkable feature of the DNA-encoded LAMP-targeted antigens has been the dramatic increase in antibody-mediated responses of immunized mice. Similar findings have been obtained with the five immunized macaques, each of which showed strong humoral immune responses (Figure 8) . The strength of these responses by the individual macaques followed the same pattern as the T-cell responses. High anti-gag IgG antibody titers were present in serum after immunization with hLAMP/gag, indicating effective priming. Four of the five vaccinated macaques (#3119, 3162, 3159 and 3117) developed antibodies against HIV-1 after the second immunization and high antibody titers were achieved by these four macaques following the third DNA immunization at week 14. The remaining macaque (#3125), which showed the weakest T-cell response, also elicited a relatively weak antibody response as compared to the other 4 macaques ( Figure 8A ). The third DNA immunization worked as a booster for all the macaques, and antibody titers reached their highest values after the 5th injection (at week 38). The end-dilution titers of the IgG antibodies achieved after four hLAMP/gag immunizations ranged from 2,700 to 24,300 ( Figure 8B ).
Serum samples of the immunized macaques were also assayed for IgA production, Significant levels were detected in three (#3119, 3159 and 3162) of the immunized macaques ( Figure 9A ). IL-6 is a key cytokine for terminal differentiation of B-cells into IgA-secreting plasma cells in both the mouse and human systems [29] [30] . Interestingly, IL-6 production was seen in the same three macaques ( Figure 9B) , correlating with the plasma IgA response. The presence of Gag-specific IgA in external secretions, including mouth swabs and nasal and rectal washes collected after four DNA immunizations, was also assayed ( Figure 9C ). The levels of IgA antibodies detected in mouth swabs and nasal and rectal washes varied remarkably among the individual macaques; however, comparatively higher IgA antibodies were found in nasal washes of all the five macaques.
Serum samples collected from the five macaques at week 24, after four DNA immunizations, were analyzed individually in ELISA assays against each of the 20-aa Gag peptides, overlapping by 10-aa ( Figure 10 ). The repertoires of peptides recognized by each of the macaque sera were very similar; all of the animals reacted with the same 13 of the 49 Gag 20-aa peptides tested. Three peptides containing B-cell determinants were located at the aminoterminal, whereas, most of the peptides recognized were located in the carboxy-terminal region of the Gag protein. These results from immunized macaques support the conclusion that vaccination with an hLAMP/gag chimera can prime a broad B-cell response [24] .
This study demonstrates that Rhesus macaques immunized with a DNA plasmid vaccine-encoding gag as an hLAMP/gag chimera develops strong antigen-specific humoral responses as well as CD4 + and CD8 + T-cell responses. Previous studies by others with candidate DNA vaccines have shown protection of small animals against pathogenic challenges [31] ; however, their performance in primates has generally been disappointing. Most naked DNA vaccines have produced sub-optimal immune responses, even with repeated boosting, with only moderate T-cell responses when compared to live-attenuated virus or recombinant virus vaccines and very low or no humoral responses. In contrast, hLAMP/gag DNA immunization elicited potent CD4 + T-cell as well as Gagspecific CD8 + T-cell responses in macaques after only a few DNA immunizations. The responses included highly significant IgG antibody titers after two DNA immunizations in four of the five immunized macaques and IgA responses in serum and nasal washes. All of the macaques showed a high IgG antibody titer after three DNA immunizations, with a rapid and enhanced immune memory response with the fourth and fifth immunization.
The breadth of the T and B cell repertoire elicited by DNA HIV vaccines is thought to be important for pathogen control, perhaps by preventing the selection of escape mutants. We have previously reported that immunization of BALB/c mice with LAMP-targeted Gag increases the breadth of B-and T-cell responses. Moreover, others have shown that human dendritic cells transfected with LAMP-targeted HIV nef are able to induce the activation of an increased repertoire of T-cells isolated from infected patients [26] . In this study, each of the four macaques tested, produced Gag-specific IFN-c + responses to many Gag 15aa peptide pools, indicating a broad range of T-cell responses. A question that remains to be investigated is whether this result reflects a true increase in the number of new epitopes being recognized as a result of hLAMP/gag administration or whether the ability of hLAMP/gag to increase the overall magnitude of the cellular immune response simply enhances our ability to detect epitopes that would otherwise have been below the limit of detection.
We also mapped B-cell epitopes of linear, 20-aa Gag peptides with serum samples obtained from the macaques after three DNA immunizations with the hLAMP/gag chimera. The results of these analyses indicated that some of the peptides behaved as dominant epitopes and induced strong B-cell activation in all five macaques. These include two dominant peptides located in the aminoterminal portion of the molecule, and 10 peptides located in the carboxy-terminal portion of the Gag protein. The amino-terminal region is known for its antigenic properties [32] [33] [34] and has been reported to contain both B and T-cell epitopes and to be relatively conserved among European HIV-1 isolates [33, 35] . The carboxyterminal region is also known to bind antibodies developed during natural HIV-1 infection in humans [36] .
Our studies also showed that IgA antibodies were present in the serum and external secretions of the hLAMP/gag-immunized macaques. Furthermore, IL-6 production was detected in three of the five immunized macaques. IL-6 is known to play a key role in the terminal differentiation of IgA-committing B cells into IgAsecreting plasma cells in both mice and humans [29] [30] . In this study, the increased production of IL-6 by Gag-specific CD4 + T cells is consistent with the induction of HIV-specific IgA B-cell responses in addition to systemic IgG antibody responses. IgA and IgG antibodies may function as a first line of defense, preventing HIV/SIV adherence to the mucosal surface or interfering with viral replication through secretory IgA [37] .
Although T-cell immune responses induced by DNA immunization are generally moderate, previous studies have demonstrated that DNA prime is very important in heterologous prime-boost immunization regimens with viral vectors. The prime-boost formulations have been shown to induce strong cellular immune responses and protection in malaria [38] [39] and SIVmac [40] [41] models. Moreover, the DNA prime and viral boost approach has been shown to be important in increasing the breadth of the response repertoire of viral vector vaccines [42] , thereby contributing to the overall immunological protection. There is growing consensus that plasmid DNA represents a particularly good prime immunogen. Therefore, considerable work is now being done to explore the use of bimodal vaccine regimens in which the plasmid DNA is used to prime the immune response and a live recombinant vector is used to boost that immunity [43] . These studies collectively suggest that more work is needed before a DNA approach alone or a DNA prime followed by a viral vector boost is able to completely control the pathogenic challenge in these model systems. A recent report has shown consistent and strong CTL responses to Gag in macaques immunized with DNA_CRL 1005-adjuvant Gag plasmids and boosted with rAd5 encoding gag [44] . The studies have established that a significant percentage of humans respond to both the DNA and adenovirus approaches, and more evaluation of further potent DNA vaccines is clearly warranted.
The current study was limited by the small number of animals and the lack of an HIV challenge system to assess the protective efficacy afforded by the HIV hLAMP/gag DNA vaccine. A further goal is to test the effect of LAMP targeting on additional relevant antigens of the SIV challenge model, in collaboration with the G. Pavlakis and B. Felber group (Human Retrovirus Section, Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA).